A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Sapanisertib (Primary) ; Bevacizumab
- Indications Endometrial cancer; Fallopian tube cancer; Glioblastoma; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- 12 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 14 May 2018 Planned primary completion date changed from 31 Mar 2018 to 31 Dec 2018.
- 01 Dec 2017 Planned primary completion date changed from 31 Oct 2016 to 31 Mar 2018.